#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Usher's syndrome Hereditary hypophosphataemic rickets Acute promyelocytic leukaemia Wolfram syndrome Sarcoma Glomerulonephritis chronic Follicular lymphoma stage III T-cell lymphoma Kearns-Sayre syndrome Systemic sclerosis pulmonary Enteritis Glomerulonephritis membranoproliferative Friedreich's ataxia Epilepsy with myoclonic-atonic seizures Nephroblastoma More trials…

    Learn about Rare Diseases

    Congenital hypotransferrinaemia – Trials in Disease Splenic marginal zone lymphoma – Life with Disease IgA nephropathy – Diagnostics Antithrombin III deficiency – Basic Information Pituitary-dependent Cushing’s syndrome – Basic Information Leukoencephalopathy – Treatment Thrombotic thrombocytopenic purpura – Basic Information Pulmonary fibrosis – Treatment Sarcoidosis – Life with Disease Alternating hemiplegia of childhood – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tebipenem Pivoxil Hydrobromide Dostarlimab AZD0516 Vixarelimab Hydroxycarbamide Lebrikizumab Dasatinib Potassium Chloride Cefixime Trihydrate E2814 Transcon Il-2Β/Γ ORG-129 Ptg-Carcik-Cd19 Flutamide Mbf-118 Ucart20X22 Nintedanib Myrrh Tumour Detection Nms-03592088 More therapies…

    Learn about Your Condition

    Thymoma Turner's syndrome Neonatal respiratory failure Primary myelofibrosis Endometrial cancer stage I Underweight Tumour thrombosis Hepatic neoplasm Type 1 diabetes mellitus Ewing's sarcoma Neonatal asphyxia Small cell lung cancer Peripheral artery restenosis Vertebrobasilar stroke Albuminuria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Smite Aija practice in Dermatology

Smite Aija practice in Dermatology

Rigas street 3-1, Talsi, 3201, Latvia

Want to learn more about this study or check if you can participate? Contact us.

  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Zasocitinib
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rocatinlimab
    Croatia Czechia Germany Greece Hungary Italy +6

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Austria Estonia France Germany Hungary Latvia +3

  • Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zasocitinib
    Bulgaria Czechia France Germany Hungary Italy +3

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!